{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T13:56:48Z","timestamp":1777730208670,"version":"3.51.4"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00120-026-02815-6","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T19:11:10Z","timestamp":1774897870000},"page":"498-505","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neue Leitlinie \u201eSupportivtherapie\u201c\u00a0\u2013 was ist f\u00fcr den Urologen relevant?","New guideline for supportive care\u2014what is relevant for urologists?"],"prefix":"10.1007","volume":"65","author":[{"given":"D\u00e9sir\u00e9e Louise","family":"Dr\u00e4ger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Protzel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"key":"2815_CR1","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF) (2025) Supportive Therapie bei onkologischen PatientInnen, Langversion 2.0, 2025, AWMF-Registernummer: 032-054OL. https:\/\/www.leitlinienprogrammonkologie.de\/leitlinien\/supportive-therapie\/. Accessed 7.12.2025"},{"key":"2815_CR2","volume-title":"Supportive Care in Oncology","author":"S3-Leitlinie Supportivtherapie","year":"2016","unstructured":"S3-Leitlinie Supportivtherapie (2016) Supportive Care in Oncology. Karger Publishers"},{"key":"2815_CR3","unstructured":"Deutsche Krebsgesellschaft e.\u202fV., Leitlinienprogramm Onkologie, www.krebsgesellschaft.de"},{"key":"2815_CR4","unstructured":"OnkoSupport, Deutsche Gesellschaft f\u00fcr Supportivtherapie in der Onkologie, www.onkosupport.de"},{"key":"2815_CR5","doi-asserted-by":"crossref","unstructured":"Jakob T, Tesfamariam YM, Macherey S et\u00a0al. (2020) Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a\u00a0network meta-analysis. Cochrane Database Syst Rev 12(12)","DOI":"10.1002\/14651858.CD013020.pub2"},{"key":"2815_CR6","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF) (2025) S3-Leitlinie Prostatakarzinom, Langversion 8.1. https:\/\/www.leitlinienprogrammonkologie.de\/leitlinien\/prostatakarzinom\/. Accessed 7.12.2025"},{"key":"2815_CR7","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF) (2020) Palliativmedizin f\u00fcr Patienten mit einer nicht-heilbaren Krebserkrankung, Langversion 2.2, 2020, AWMF-Registernummer. https:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/palliativmedizin\/. Accessed 7.12.2025"},{"issue":"4","key":"2815_CR8","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1111\/bju.14516","volume":"123","author":"C Pascoe","year":"2019","unstructured":"Pascoe\u00a0C, Duncan\u00a0C, Lamb\u00a0BW, Davis\u00a0NF, Lynch\u00a0TH, Murphy\u00a0DG, Lawrentschuk\u00a0N (2019) Current management of radiation cystitis: a review and practical guide to clinical management. BJU Int 123(4):585\u2013594","journal-title":"BJU Int"},{"issue":"3","key":"2815_CR9","doi-asserted-by":"publisher","first-page":"281","DOI":"10.23736\/S2724-6051.21.04539-0","volume":"74","author":"M Marchioni","year":"2022","unstructured":"Marchioni\u00a0M, Francesco\u00a0P, Campi\u00a0R, Carbonara\u00a0U, Ferro\u00a0M, Schips\u00a0L, Gomez Rivas\u00a0J, Papalia\u00a0R, Scarpa\u00a0RM, Esperto\u00a0F (2022) Current management of radiation cystitis after pelvic radiotherapy: a systematic review. Minerva Urol Nephrol 74(3):281\u2013291","journal-title":"Minerva Urol Nephrol"},{"issue":"1","key":"2815_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s11934-024-01238-0","volume":"26","author":"E Neckonoff","year":"2024","unstructured":"Neckonoff\u00a0E, Anderson\u00a0CB (2024) Advancements in Understanding and Managing Radiation Cystitis: A Comprehensive Review. Curr Urol Rep 26(1):1","journal-title":"Curr Urol Rep"},{"issue":"12","key":"2815_CR11","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","volume":"33","author":"J Haanen","year":"2022","unstructured":"Haanen\u00a0J, Obeid\u00a0M, Spain\u00a0L, Jordan\u00a0K, Larkin\u00a0J et\u00a0al (2022) Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 33(12):1217\u20131238","journal-title":"Ann Oncol"},{"key":"2815_CR12","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider\u00a0BJ, Naidoo\u00a0J, BSantomasso\u00a0BD, Lacchetti\u00a0C et\u00a0al (2021) Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J\u00a0Clin Oncol 39:4073\u20134126","journal-title":"J Clin Oncol"}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-026-02815-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-026-02815-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-026-02815-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:57:48Z","timestamp":1777460268000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-026-02815-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,30]]},"references-count":12,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2815"],"URL":"https:\/\/doi.org\/10.1007\/s00120-026-02815-6","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"value":"2731-7064","type":"print"},{"value":"2731-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,30]]},"assertion":[{"value":"31 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"D.L.\u00a0Dr\u00e4ger und C.\u00a0Protzel geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}